Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response.

Jennifer L Mcquade ,Adi Diab,Guo Chen,Lauren Simpson,Ryan J Sullivan,Roland L Bassett,Rosalind Mouton,Patrick Hwu,Michael T Tetzlaff ,Isabella C Glitza ,Rodabe N Amaria ,Alexandre Reuben ,Jennifer A Wargo ,Wen‐Jen Hwu ,Aron Y Joon ,Sapna Patel ,David J Panka ,Alexander J Lazar ,Kevin Kim

doi:10.1200/jco.2015.33.15_suppl.e20051

Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response.

Jennifer L Mcquade , Adi Diab + Show 17 more

https://doi.org/10.1200/jco.2015.33.15_suppl.e20051

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2015
Citations: 1

Affiliation: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Harvard University, Beth Israel Deaconess Medical Center, California Pacific Medical Center

#Molecular Predictors Of Response #BRAF Inhibitor Monotherapy #Combination Of Dabrafenib #BRAF V600 Mutations #Combination Of Trametinib #Metastatic Melanoma #Metastatic Melanoma Patients #Melanoma Patients #Clinical Predictors #V600 Mutations

Abstract
Full-Text
Similar Papers

Abstract

Listen

e20051 Background: The combination of dabrafenib (D) and trametinib (T) has demonstrated clinical responses in a subset of metastatic melanoma (MM) patients (pts) with BRAF V600 mutations after pro...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response.